| Document |
Document Title |
|
WO/2022/241031A1 |
Described herein are chemoembolization compositions comprising an anti-cancer drug, methods of making, and their use in treating cancer, such as liver cancer.
|
|
WO/2022/237864A1 |
It has been established that inhibition of macropinocytosis in cancer cells enhances the anti-cancer efficacy of photodynamic therapy (PDT). Methods for treating cancer in a subject in need thereof include administering to a subject with...
|
|
WO/2022/237247A1 |
Disclosed is the use of cellular microparticles in the treatment of respiratory viral pneumonia. Tumor-cell-derived microparticles (MPs), which comprise a cellular vesicle released by an apoptotic tumor cell. The cellular vesicle express...
|
|
WO/2022/233102A1 |
The present disclosure provides a method for the treatment or prophylaxis of coronavirus infection, comprising administering a therapeutically effective amount of an immunomodulator to a subject in need thereof or at risk of coronavirus ...
|
|
WO/2022/234054A1 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting fr...
|
|
WO/2022/234409A1 |
The present invention relates to a pharmaceutical combination comprising a SHP2 inhibitor and a CDK4/6 inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment o...
|
|
WO/2022/234888A1 |
The present invention relates to a pharmaceutical composition for treating macular degeneration, containing an imidazoline derivative compound as an active ingredient. A composition containing an imidazoline derivative compound or a phar...
|
|
WO/2022/235514A1 |
A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs. A method of treating a patient, ...
|
|
WO/2022/235482A1 |
The present disclosure includes compositions and methods for treating gastrointestinal inflammatory disease and/or cancers. In certain aspects, the disclosure includes an isolated cell comprising a nucleic acid vector comprising a gene e...
|
|
WO/2022/236256A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2022/234076A1 |
The invention relates to a pharmaceutical dosage form comprising Tapentadol or a physiologically ac- ceptable salt thereof for use in the treatment of pain in a patient who is or who was previously infected with a coronavirus.
|
|
WO/2022/234064A1 |
The invention relates to one or more high-concentration capsaicinoid topical dose units for use in the treatment of a neuropathic condition, preferably neuropathic pain, in a patient who is or who was previously infected with a coronavir...
|
|
WO/2022/235050A1 |
The present invention relates to a composition for inhibiting tumor growth, containing an extract of Sanguisorba officinalis as an active ingredient. It has been identified that a Sanguisorba officinalis extract binds to PD-L1 on cancer ...
|
|
WO/2022/235566A1 |
The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic c...
|
|
WO/2022/235613A1 |
This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.
|
|
WO/2022/235832A1 |
The present disclosure relates to methods and compositions to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified lymphocytes such as human T ...
|
|
WO/2022/235500A1 |
A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.
|
|
WO/2022/233460A1 |
The present invention belongs to the field of medicine, and more precisely to the field of medicine useful in the treatment of cardiac diseases with contributing mitochondrial dysfunction. The present invention relates to a composition a...
|
|
WO/2022/235874A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2022/236257A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2022/232168A1 |
There is disclosed a combination oral dosage form pharmaceutical composition comprising a bitter receptor agonist and a gut-signaling compound, i.e., a gut-signaling peptide analog and/or gut-signaling hormone enhancer. And there is disc...
|
|
WO/2022/230987A1 |
A prophylactic or therapeutic agent for myopathy, containing a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.
|
|
WO/2022/230795A1 |
Provided is an agent or composition that is useful in, inter alia, the prevention, treatment, and/or improvement of neurodegenerative disease.　The agent or composition is configured to contain a component that suppresses the expression...
|
|
WO/2022/229932A1 |
Provided are methods of treating, minimizing and/or inhibiting atrophy associated with retinal hypoxia, comprising administering a pharmaceutical composition comprising an HIF inhibitor to a subject having retinal hypoxia. The HIF inhibi...
|
|
WO/2022/228651A1 |
The present invention relates to a compound according to the general formula (I) for use in the treatment or prophylaxis of a disease associated with an interaction of a receptor comprising a sialic acid-containing sugar chain with a cog...
|
|
WO/2022/232494A1 |
The present disclosure relates to Compound (1), or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) in a human female subject during the subject's postnatal period, wherein the subjec...
|
|
WO/2022/229575A1 |
The invention relates to compounds capable of inducing autophagy and metabolic reprogramming and to the use thereof as cardioprotectors, in particular in the context of anti-cancer therapy.
|
|
WO/2022/227555A1 |
The present invention relates to a cabazitaxel-fatty alcohol prodrug and the construction of a self-assembled nanoparticle thereof, and specifically relates to a disulfide bond-bridged redox dual-sensitive cabazitaxel-fatty alcohol prodr...
|
|
WO/2022/232417A1 |
A method of treating multiple myeloma (MM) in a subject in need thereof, comprising the steps of: obtaining a sample from the subject; determining the presence or absence of one or more RAS mutations in the sample; and administering a th...
|
|
WO/2022/232371A1 |
Disclosed are sterile aqueous choline salt compositions, their preparation, and methods of use. Also disclosed are methods to treat choline deficiency, intestinal failure associated liver disease (IFALD), and fatty liver disease. Additio...
|
|
WO/2022/231357A1 |
Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin...
|
|
WO/2022/232504A1 |
The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates ...
|
|
WO/2022/229152A1 |
The present invention relates to a combination product comprising an antibiotic and at least one non-pathogenic microorganism for simultaneous, separate, or sequential use in preventing emergence of resistance to the antibiotic when trea...
|
|
WO/2022/232790A1 |
Provided are methods for treating an ocular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucl...
|
|
WO/2022/229264A2 |
The present invention relates to uses of and methods of using activators of Nrf2 to enhance natural killer (NK) cell and/or T cell activity and/or survival, particularly in response to stress. The NK cells and/or T cells can be utilised ...
|
|
WO/2022/229368A1 |
The present invention relates to methods for treating vascular inflammation, atherosclerosis and related disorders in a subject using a lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) binding protein, such as an anti-LOX-...
|
|
WO/2022/228399A1 |
The present invention relates to the technical field of medicine, in particular to a tricyclic USP1 inhibitor compound, a pharmaceutically acceptable salt thereof, an ester, a deuterated substance or a stereoisomer thereof, a pharmaceuti...
|
|
WO/2022/231311A1 |
The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which canc...
|
|
WO/2022/229302A1 |
The present invention relates to a combination of a FXR agonist and a TLR3 agonist having a synergistic effect and its use for the treatment of diseases and disorders.
|
|
WO/2022/230990A1 |
The present invention is directed to a nucleic acid analog in which a cationic artificial nucleic acid and a hydrophilic polymer are bound to each other. The cationic artificial nucleic acid has a backbone structure consisting of: buildi...
|
|
WO/2022/228497A1 |
The present invention relates to the use of a medicament in treatment of a tumor disease. In particular, the present invention provides the use of a biologically active conjugate represented by formula (I) in treatment of a tumor disease...
|
|
WO/2022/231377A1 |
The present invention relates to a pharmaceutical composition comprising a novel compound or a pharmaceutically acceptable salt thereof for prevention or treatment of refractory cancer. When administered together with an anticancer agent...
|
|
WO/2022/222596A1 |
A prostate cancer treatment product, comprising deslanoside and adjuvants, the concentration of deslanoside is greater than or equal to 1 mg/kg and less than or equal to 10 mg/kg, and the adjuvants comprise medical ethanol, medical grade...
|
|
WO/2022/226347A1 |
Provided herein are pharmaceutical compositions and related methods for treating ophthalmic diseases. The method entails administering to the patient an effective amount of a CSF1R inhibitor, such as an anti-CSF1R antibody. The methods a...
|
|
WO/2022/225868A1 |
Disclosed are compounds comprising ketamine (2-(2-chlorophenyl)-2-(methylamino)- cyclohexanone) chemically conjugated to one or more oxoacids, amino acids, polyethylene glycols (PEG or PEO), peptides, phosphates, and/or vitamin compounds...
|
|
WO/2022/223544A1 |
A method of treating cancer (e.g., pancreatic cancer) in a subject is disclosed. The method includes administering to a cell or a subject in need thereof an effective amount of a mechanistic target of rapamycin inhibitor and an effective...
|
|
WO/2022/222261A1 |
A hexokinase 2 inhibitor screening method and an application of a small molecule compound in the preparation of an antitumor drug. The screening method comprises: mixing a candidate inhibitor with a buffer solution, incubating, and termi...
|
|
WO/2022/225045A1 |
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The present invention provides a therapeutic or prophylactic agent for cachexia accompanied by g...
|
|
WO/2022/223543A1 |
The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benz
amide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunot...
|
|
WO/2022/222138A1 |
Provided is the use of a substance for inhibiting PTBP1 gene expression in the preparation of a drug for treating Alzheimer's disease. Further provided is the use of the PTBP1 gene as a therapeutic target in screening a drug for treating...
|
